NCT03206203
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with leptomeningeal disease; Patients with known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases- see trial for details; Male patients
https://ClinicalTrials.gov/show/NCT03206203